Clinical trial
Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI.
NCT00430040 · University at Buffalo, Other · Terminated
Key facts
| NCT number | NCT00430040 |
|---|---|
| Title | Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI. |
| Official title | Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI:Effects on Oxidative Stress and Inflammation. |
| Lead sponsor | University at Buffalo, Other |
| Collaborators | GlaxoSmithKline Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2, Hypertension |
| Intervention type | Drug |
| Interventions | Carvedilol Controlled Release (CR), lisinopril |
| Enrollment | 14 |
| Start date | Feb 1, 2007 |
| Primary completion | May 1, 2013 |
| Completion | May 1, 2013 |
| First posted | Feb 1, 2007 |
| Last update posted | Apr 16, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: